• SPX
  • $5,978.88
  • -0.11 %
  • -$6.50
  • DJI
  • $43,947.85
  • -0.02 %
  • -$10.35
  • N225
  • $38,535.70
  • -0.48 %
  • -$185.96
  • FTSE
  • $8,067.50
  • 0.46 %
  • $37.17
  • IXIC
  • $19,195.11
  • -0.19 %
  • -$35.63

Bristol Myers's stock soars after AbbVie's schizophrenia-drug trial disappoints

By MarketWatch   |   Nov 11, 2024 at 11:00 AM EST
Bristol Myers's stock soars after AbbVie's schizophrenia-drug trial disappoints

Bristol Myers Squibb's stock rose by 12.5% following AbbVie's announcement of disappointing trial results for their new schizophrenia drug, causing AbbVie's shares to drop by 12.4%.

Read More

Did you find this insightful?


We are preparing, please wait

×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.